The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Elderly

Completed

• Conditions: Aged, 80 and Over; Neurocognitive Disorders; Dementia; Hypertension
• Interventions: Drug: Antihypertensive Agents

• Registration Number: NCT05845736
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Neurocognitive disorders and hypertension occur commonly with aging. While, by definition, older adults are at high cardiovascular risk, there is no guideline exist currently on blood pressure management of elderly hypertension. However, studies have shown that in aging adults, high blood pressure helps prevent against cognitive decline, and low blood pressure on antihypertensive drugs could accelerate it. This study aims at investigating if pharmacological treatment of hypertension in the very elderly is influenced by presence and severity of neurocognitive disorders. Our research hypothesis is that the drug management of hypertension in patients 80 years of age or older more is all the less aggressive as the neurocognitive disorders are advanced.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-01-01
• Primary Completion: 2022-01-01
• Study Completion: 2022-12-12
• Study First Submitted: 2023-03-26
• Study First Submitted QC: 2023-04-25
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-04
• Study First Posted: 2023-05-06
• Last Update Posted: 2023-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 353

Inclusion Criteria

• to be 80 years of age
• with history of hypertension and/or on hypertensive drug(s)

Exclusion Criteria

• legal protection measure.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
control group	Antihypertensive Agents	absence of neurocognitive disorder (ND), Mini-Mental State Examination (MMSE) from 27 to 30 inclusive
mild neurocognitive disorder	Antihypertensive Agents	MMSE from 21 to 26 inclusive
moderate neurocognitive disorder	Antihypertensive Agents	MMSE from 11 to 20 inclusive
severe neurocognitive disorder	Antihypertensive Agents	MMSE less than or equal to 10

Primary Outcome Measures

Name	Time	Method
number of antihypertensive agents	during inclusion	among ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker

Secondary Outcome Measures

Name	Time	Method
orthostatic hypotension	during inclusion	a systolic blood pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at least 10 mm Hg within three minutes of standing
class of antihypertensive medications	during inclusion	among ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker
systolic and diastolic blood pressure	during inclusion	blood pressure measured with upper arm cuffs

Trial Locations

Locations (1)

Centre Hospitalier Régional Universitaire de Nancy; 🇫🇷 Nancy, France